### **Overview** Dr. Reddy’s Laboratories Ltd., headquartered in Hyderabad, India, is a globally integrated science-led pharmaceutical company established in 1984. With operations in over 80 countries and a workforce of approximately 26,900 employees, the company serves an estimated 756 million patients worldwide, including 192 million in low- and middle-income countries. It operates through two core segments: **Global Generics (GG)** and **Pharmaceutical Services & Active Ingredients (PSAI)**, with the "Others" segment comprising its clinical-stage biotech and innovation arms. The company is guided by the strategic vision **“Securing our core, while building our future”**, focusing on market leadership in selected therapeutic areas while investing in future growth engines such as biologics, nutraceuticals, digital therapeutics, and new chemical and biological entities (NCEs/NBEs). Its mission centers on accelerating access to affordable and innovative medicines through science-driven development, strategic partnerships, and digital transformation. --- ### **Strategic Pillars & Business Focus** Dr. Reddy’s growth strategy is anchored on three pillars: 1. **Leadership in Chosen Spaces** – Market leadership in GI, oncology, diabetes, CNS, and biosimilars. 2. **Operational Excellence** – Digital transformation, Industry 4.0 integration, and cost optimization. 3. **Patient-Centric Innovation** – Differentiated product development and integrated care solutions. Key therapeutic areas include: - **Oncology**: Core pillar with biosimilars, immunotherapies, and CAR-T development. - **Gastrointestinal (GI)**: Market-leading brands (Omez®, Razo®, Vono™) and innovative therapies. - **Diabetology**: Entry into GLP-1 analogs (e.g., semaglutide) and digital care. - **Central Nervous System (CNS)**: Anti-vertigo, neurology, and addiction management. - **Cardiovascular, Pain, and Anti-Infectives**: Branded and generic offerings. Markets: USA, India, Europe, Russia & CIS, Brazil, China, South Africa, and Australia. --- ### **Recent Strategic Developments (2024–2025)** #### **1. Expansions in Biologics and Biosimilars** Dr. Reddy’s has solidified its position in the global biosimilars market with over 25 years of end-to-end integrated capabilities in development, manufacturing, and commercialization. As of 2025, the company: - **Markets six biosimilars in India** and select products in over 30 countries. - Secured **positive opinion from the European Medicines Agency (EMA)** for its **denosumab biosimilar (AVT03)** and **SEC approval in India for semaglutide injection**, marking entry into the high-growth GLP-1 market. - Launched **Versavo® (bevacizumab biosimilar) in the UK** and commercialized **pegfilgrastim in the U.S. and Europe via a partner**. - Advanced **abatacept (DRL_TC)** into **Phase III trials**; in-licensed **ustekinumab and golimumab biosimilars** for Southeast Asia. - Entered exclusive or semi-exclusive agreements with **Alvotech** and **Henlius Biotech** to commercialize denosumab and daratumumab biosimilars in the U.S., Europe, and UK. #### **2. Innovation & R&D Investments** - **R&D spend** maintained at **8.4% of revenue in FY2025**, focused on **complex generics**, **biosimilars**, **peptides**, and **oncology assets**. - Filed **249 generic dossiers globally**, including **10 ANDAs and 111 DMFs**; 73 ANDAs and 3 NDAs pending with the U.S. FDA, including **46 Paragraph IV filings** with potential ‘First-to-File’ exclusivity. - **Aurigene Oncology**, a wholly-owned subsidiary, has: - Reported **positive Phase I results for India’s first autologous CAR-T therapy (DRL-1801)** for multiple myeloma. - Earned **U.S. FDA IND approval for AUR-112 (MALT1 inhibitor)** and **AUR-110 (solid tumor candidate)**. - Signed global licensing deals (e.g., with Olema Oncology) and leveraged AI-driven platforms for drug discovery with IICT. - **API Innovation**: Developed a cost-effective process for **Palbociclib** API and launched generic **palbociclib capsules in India** at **85% lower price** than the innovator. #### **3. Strategic Acquisitions and Portfolio Expansion** - **Nicotine Replacement Therapy (NRT) Acquisition**: Acquired **Haleon’s NRT portfolio** (including **Nicotinell®, Nicabate®, Habitrol®, Thrive®**) for **GBP 500 million** in 2024. As of October 2025, **67% of integration by value is complete**, covering Canada, Australia, and key Western European markets. Southern Europe, Israel, and Taiwan are next. - **Nicotinell** is the **world’s second-largest NRT brand** (excluding U.S.). - **STUGERON® Acquisition**: Acquired **Stugeron® (cinnarizine)** across **18 APAC and EMEA markets** for **$50.5 million**, with India and Vietnam as key growth markets. This strengthens its **CNS portfolio**, especially in vertigo management. #### **4. Consumer Health & Nutraceuticals Growth** - **Joint Venture with Nestlé India**: Formed a **51:49 JV**, **Dr. Reddy's and Nestlé Health Science Limited**, for science-backed nutraceuticals in India. Launched brands like **Nature’s Bounty**, **Resource**, and integrated **Rebalanz** and **Becozinc**. - **Acquired MenoLabs®** in the U.S. to deepen presence in **women’s wellness and menopause care**. - Launched **Premama®** (maternal health) and **Histallay®** (allergy, UK) in OTC markets. - Aims to build a **branded consumer health business in Europe**, anchored on NRT portfolio and OTC wellness. #### **5. Digital & Integrated Care Platforms** - Launched **DailyBloom™** – India’s first **integrated digital care program** for **Irritable Bowel Syndrome (IBS)**, supported by patient data and behavioral insights. - Launched **Nerivio®**, a **U.S. FDA-approved, drug-free wearable device** for **migraine** using Remote Electrical Neuromodulation (REN). Now available in India, Germany, South Africa, and select markets. - Digital transformation via **OpsNext**: FTO-3 plant certified as a **World Economic Forum Digital Lighthouse**, utilizing **IIoT, digital twins, automation, and cloud platforms**. - Migrated to **cloud-based SAP ERP** and launched **Project O2** for integrated business and supply chain planning. --- ### **Key Product Launches and Approvals (2024–2025)** | Product / Program | Market | Date | Details | |------------------|--------|------|--------| | **Semaglutide Injection** | India | Oct 2025 | SEC-approved; first local entry into GLP-1 market. | | **Linaclotide (Colozo®)** | India | Oct 2025 | Treatment for chronic constipation; expands GI portfolio. | | **Tegoprazan (PCAB®)** | India | Oct 2025 | Potassium-competitive acid blocker developed with HK inno.N. | | **Denosumab biosimilar** | EU | Oct 2025 | Positive CHMP opinion; potential EU launch soon. | | **COYA 302 (ALS therapy)** | U.S. | Oct 2025 | IND accepted; partnered with Coya Therapeutics. | | **Toripalimab (Zytorvi®)** | India | Jun 2025 | PD-1 inhibitor approved for nasopharyngeal carcinoma; launched globally. | | **Elobixibat (BixiBat®)** | India | Jun 2025 | First-in-class therapy for chronic constipation. | | **Rituximab Biosimilar (ITUXREDI®)** | Europe/UK | Jun 2025 | Approved by EMA and MHRA for oncology and autoimmune indications. | --- ### **Global Presence & Market Performance** - **U.S. Generics Market**: Ranked **8th**, with focus on **injectables, peptides, and complex generics**. - **India Market**: Ranked **10th**, targeting top-five position via acquisitions and in-licensing. - **Europe**: Growing at **75% YoY (FY2025)**; strong pipeline of biosimilars (rituximab, bevacizumab, denosumab, abatacept). - **Revenue**: $3.8 billion (unspecified period); **Europe segment generated €35.9B**, contributing **11%** of total revenue. - **Manufacturing & R&D**: 23 manufacturing sites and **9 R&D centers** globally. --- ### **Partnerships & Collaborations for Access** - **Lenacapavir Access Initiative**: Royalty-free license from **Gilead** to manufacture and commercialize **HIV prevention drug** in **over 120 low- and middle-income countries**. - Partnered with **Unitaid, CHAI, and Wits RHI** to accelerate distribution. - **Vaccine Distribution**: Exclusive partnership with **Sanofi** to distribute vaccines in India; became **2nd-largest player** in the Indian vaccine segment. - **Innovative Licensing**: In-licensed **Vonoprazan (Takeda)**, **Cyclophosphamide (Ingenus)**, **Toripalimab (Junshi)**, and **Elobixibat**. - **CAR-T Expansion**: Exclusive agreement with **Wellington Zhaotai Therapies** for CAR-T asset **WL-002** in India. - **Global Biosimilar Supply Agreements**: With **Bio-Thera**, **Alvotech**, **Henlius**, and **Zhejiang Hisun** for commercialization and co-development. --- ### **Sustainability & ESG Commitment** - **Pioneer in ESG**: Publishing **sustainability reports since 2004**; included in **Dow Jones Sustainability World Index (2023)**. - **Zero Liquid Discharge (ZLD)**: Early adopter of membrane technology for wastewater treatment. - **Digital Paani**: Automates STP/ETP operations using sensors and cloud analytics. - **ESG Goals**: Environmental stewardship, affordable healthcare, gender diversity, and robust governance. ---